Antiviral prodrugs and nanoformulations thereof

1. A compound of formula I:

or a pharmaceutically acceptable sat thereof,

wherein R is a saturated linear aliphatic chain of a length of 17 carbons.

2. A nanoparticle comprising a compound of claim 1 and a polymer or surfactant.

3. The nanoparticle of claim 2 , wherein the compound is

or a pharmaceutically acceptable salt thereof, and the polymer or surfactant is P407.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. A method of treating an HIV infection in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 4 .

6. The method of claim 5 , wherein the pharmaceutical composition is administered via injection.

7. The method of claim 5 , wherein the pharmaceutical composition is administered one time in a 3, 6, 9, 12, 18, or 24 month period.